Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.

UNLABELLED The aim of this study was to determine the human biodistribution and radiation dosimetry of (99m)Tc-RP527, a promising radioligand for the visualization of gastrin-releasing peptide (GRP) receptor-expressing human malignancies. METHODS Whole-body scans were obtained up to 48 h after intravenous injection of 555 MBq (99m)Tc-RP527 in each of 6 subjects. Blood samples were taken at various times up to 48 h after injection. Urine was collected up to 48 h after injection for calculation of renal clearance and whole-body clearance. Time-activity curves were generated for the thyroid, heart, breasts in women, testes in men, and liver by fitting the organ-specific geometric mean counts, obtained from regions of interest, on the respective images as a function of the time after injection. The MIRD formulation was applied to calculate the absorbed radiation dose for various organs. RESULTS The serial whole-body images showed rapid hepatobiliary excretion, resulting in low background and potentially high-contrast imaging of the thoracic region. Imaging of abdominal tumors may prove problematic, however, because of the extensive bowel activity. (99m)Tc-RP527 was predominantly cleared by the kidneys and to a lesser extent by the gastrointestinal tract. The mean excretion in the urine (+/-SD) at 48 h after injection was 58.3 +/- 5.4 percentage of the injected activity corrected for decay to the time of injection. The highest absorbed doses were received by the excretory organs (i.e., the urinary bladder and gallbladder wall). The average effective dose of (99m)Tc-RP527 was estimated to be 0.0095 mSv/MBq. CONCLUSION The biodistribution of (99m)Tc-RP527 revealed low lung, myocardial, and liver uptake, which allowed early imaging of the supradiaphragmatic region with a favorable dosimetry (including effective dose) for administered activities required for SPECT imaging.

[1]  R. Bruzzone,et al.  Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man. , 1983, The Journal of clinical endocrinology and metabolism.

[2]  J C Reubi,et al.  Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.

[3]  D. Carney.  Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide , 1987, Regulatory Peptides.

[4]  T. McDonald,et al.  Gastrin-releasing peptide-, calcitonin gene-related peptide-, and calcitonin-like immunoreactivity in human breast cyst fluid and gastrin-releasing peptide-like immunoreactivity in human breast carcinoma cell lines. , 1989, Surgery.

[5]  J C Reubi,et al.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. , 1999, The American journal of pathology.

[6]  R. Sievert,et al.  Book Reviews : Recommendations of the International Commission on Radiological Protection (as amended 1959 and revised 1962). I.C.R.P. Publication 6. 70 pp. PERGAMON PRESS. Oxford, London and New York, 1964. £1 5s. 0d. [TB/54] , 1964 .

[7]  A. Schally,et al.  Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. , 1992, Cancer research.

[8]  G. Gibson,et al.  The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.

[9]  R. Bruzzone,et al.  Bombesin effects on human GI functions , 1985, Peptides.

[10]  A. Schally,et al.  Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. , 1997, European journal of cancer.

[11]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[12]  G. Paludetti,et al.  EGF receptor expression in primary laryngeal cancer: Correlation with clinico‐pathological features and prognostic significance , 1992, International journal of cancer.

[13]  L. Yamamoto,et al.  Estrogen and progesterone receptor mrna levels in primary breast cancer: Association with patient survival and other clinical and tumor features , 1994, International journal of cancer.

[14]  L. Kaplan,et al.  Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[15]  E. Sausville,et al.  Bombesin receptor structure and expression in human lung carcinoma cell lines , 1996, Journal of cellular biochemistry. Supplement.

[16]  K. F. Eckerman,et al.  Specific absorbed fractions of energy at various ages from internal photon sources: 2, One-year-old , 1987 .

[17]  K. F. Eckerman,et al.  Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn , 1987 .

[18]  H. Beekhuis.  Population radiation absorbed dose from nuclear medicine procedures in The Netherlands. , 1988, Health physics.

[19]  T. Moody,et al.  Growth factor and peptide receptors in small cell lung cancer. , 1993, Life sciences.

[20]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[21]  J. Vennart.  Limits for intakes of radionuclides by workers: ICRP Publication 30. , 1981, Health physics.

[22]  F. Eustache,et al.  Effect of gastrin-releasing peptide on sperm functions. , 1996, Molecular human reproduction.

[23]  H. Ohki‐Hamazaki,et al.  Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse , 1997, Brain Research.

[24]  E. Rozengurt.  Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. , 1990, The American review of respiratory disease.

[25]  R. Murphy,et al.  Bombesin stimulates proliferation of human breast cancer cells in culture. , 1991, British Journal of Cancer.

[26]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.

[27]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  E. Sausville,et al.  Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. , 1991, The Journal of biological chemistry.

[29]  A. Schally,et al.  Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160 , 1992, The Prostate.

[30]  A. Schally,et al.  Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. , 1995, Cancer research.

[31]  J. Saurin,et al.  High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. , 1999, European journal of cancer.

[32]  M. Kane,et al.  Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. , 1996, Lung cancer.

[33]  A. Schally,et al.  Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. , 1994, Cancer research.

[34]  M. Ciomei,et al.  Bombesin stimulates growth of human prostatic cancer cells in vitro , 1990, Cancer.

[35]  V. Erspamer.  Discovery, Isolation, and Characterization of Bombesin‐like Peptides , 1988 .

[36]  Michael G. Stabin,et al.  Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters , 1997, European Journal of Nuclear Medicine.